APOE4: Should you join an Alzheimer's prevention trial?
Q&A with an expert who recruits APOE4 carriers into Alzheimer's trials on what they ask of you...and what to ask back.
Key takeaways · TL;DR
Q&A with an expert who recruits APOE4 carriers into Alzheimer's trials on what they ask of you...and what to ask back.
You carry APOE4. You've seen the prevention trials. And you can't tell whether joining one is brave, smart, or a risk you shouldn't take.
Maybe you've opened a listing on ClinicalTrials.gov and closed it more confused than before. Maybe you've read a forum thread where someone got placebo for two years and felt cheated. Maybe the word ARIA stopped you cold.
So I asked someone who has spent her career on the other side of that decision.
Jessica Langbaum, PhD, leads Alzheimer's prevention research at Banner Alzheimer's Institute and runs the Alzheimer's Prevention Registry. Her first answer was about her own field:
We don't make it easy for folks.
Here's what she told me, so it's easier for you.
Prefer to watch? The full conversation is here:
Key takeaways
Before you say yes, ask yourself three things: do you have the time, do you want to learn new results (amyloid PET, p-tau217), and is the risk of an unapproved drug acceptable to you.
Enrolment usually takes weeks to a few months. Many trials need a study partner, often by phone.
Ask what the study covers: transport, parking, car service, hotels. Many studies do.
You stop a supplement or medicine only if the protocol excludes it. With no approved prevention treatment yet, a washout is considered ethical.
Placebo exists because some drugs did harm. In many trials, placebo participants move onto the drug later.
ARIA risk is highest with two copies of APOE4. Ask the trial's doctors to look at your MRI and history first.
Two copies of APOE4 raises risk. It is not a diagnosis.
Before you say yes: three questions for yourself
Do you have the time? Prevention trials are long, with a lot of visits: tests, specialists, scans. Monthly or every other month, sometimes for years.
Do you want to know? You already know your APOE4 status. But a trial may need you to learn your amyloid PET result, or your p-tau217 blood test, before you can join. "Do you want to know this information about yourself?"
Is the risk acceptable to you? Trials test drugs that aren't approved for that use yet. The informed consent lays the risks out. Ask the study team questions, and talk it through with someone you trust.
What joining actually looks like
You contact the study site. They pre-screen you by phone and may ask for your medical records. Then come several pre-screening visits over a few weeks: memory and thinking tests, blood, maybe a brain scan. If you're eligible, you're randomized centrally (the site doesn't choose your arm).
Ideally, the whole thing takes two to three months. Many studies also need a study partner, someone who can answer questions about your memory. Their part can often be done by phone.
Don't assume you pay
Ask whether the study covers transport, parking, a car service or a hotel. Many do.
Don't just assume that you'd have to cover those things out-of-pocket.
And ask for the visit schedule, with the flexibility around each visit. A trip planned for May shouldn't mean dropping out.
Would a trial make you stop your supplements?
Only if the protocol excludes them, and only for as long as it says (sometimes 30 days). The reason is safety: nobody knows yet how an experimental drug interacts with everything else.
And if that sounds unfair, Jessica explained why it isn't in prevention:
There are no approved treatments for the prevention of Alzheimer's disease, which is why it is ethical to have people come off.
Is the placebo arm wasted time?
The placebo is there for a reason. Some Alzheimer's drugs made people do worse than placebo. Without the comparison, nobody would have known.
People on placebo also get more attention, more scans and more tests than usual. And in many trials, the placebo group moves onto the drug after the blinded part. Ask about it before you join.
Two copies and ARIA
ARIA (swelling or small bleeds seen on MRI) is the risk carriers worry about most with antibody drugs, and it is highest with two copies.
Before an antibody trial, Jessica would look at the MRI first (how many microbleeds are already there), the medical history and the other medications. Then weigh it, or wait for a drug with a lower risk.
Blood tests are opening trials up
Amyloid PET scans are expensive and not available everywhere. Blood tests like p-tau217 are starting to replace them for eligibility, so you don't have to travel great distances to find out if you qualify. (In the US, these blood tests are approved only for people with symptoms; trials use them in healthy people for research.)
She also mentioned what's coming: Roche's PrevenTRON trial, NewAmsterdam's SPINOZA trial, and studies pairing a healthy lifestyle with a GLP-1 drug.
Two copies is not a sentence
Her closing message, for anyone who has just learned they carry two copies:
Having two copies of APOE4 is just a susceptibility factor.
It raises your risk. Plenty of people with two copies never develop Alzheimer's. And researchers want to know why.
The limits: every trial is different. Jessica described how trials usually work in the US; for any specific trial, the study team and the informed consent are your source.
Two places to start today: the Alzheimer's Prevention Registry (endalznow.org), open to anyone 18+, anywhere, and our free APOE4 trial finder, which lets you filter trials by site and eligibility.
Coming up next: Dr. Michael Davidson
My next conversation is with Dr. Michael Davidson, the CEO of NewAmsterdam Pharma, the company developing obicetrapib, a cholesterol-lowering pill that blocks a protein called CETP.
Why it matters for carriers: obicetrapib is the drug in SPINOZA, the NewAmsterdam trial Jessica mentioned. It's a placebo-controlled phase 2 trial in people aged 55 to 85 with preclinical Alzheimer's (brain changes before any symptoms). See SPINOZA in our Clinical Trial Engine.
Dr. Davidson is also first author of a study of obicetrapib and p-tau217, the Alzheimer's blood marker above, in people with heart disease. I explained obicetrapib in a video and full write-up.
Obicetrapib is not approved for Alzheimer's, and this is not a recommendation to take it.
I record with him on Tuesday 17 November. Phoenix members put their questions to him directly, and theirs are already coming in.
The episode is free. So why join?
The answers are free. The questions came from members.
The supplement question above wasn't mine. A Phoenix member asked it in our community. Other carriers reacted, it rose to the top, and I put it to Jessica.
That's how the interviews work inside Phoenix. Right now, members are posting their questions for Dr. Davidson, until Sunday 8 November.
Next time, it can be your question.
What you're actually joining
Jessica runs a registry that connects people with Alzheimer's prevention studies. Phoenix helps with the same step: when a clinical trial fits your profile, the app alerts you. That is one piece of what Phoenix is: your home for everything APOE4. A personalized protocol, independent guidance, and better prices on tests, supplements and devices, all in one place.
Here is what you get:
Doctors who understand APOE4. Neurologists, preventive and integrative doctors, many by telehealth, hand-picked by me or recommended by members. So you are not the one teaching your doctor about APOE4.
Blood tests at up to 70% below retail. Order them in the app and get your blood drawn at a Quest, Labcorp or BioReference lab near you. Already tested elsewhere? Upload those results too.
Supplements at up to 35% off most major brands, in the Phoenix private supplement store.
Your personal protocol. Phoenix AI brings together your genes, bloodwork, wearables and daily check-ins with the research and the real results of 700+ carriers. Each monthly review shows what to keep, what to adjust and what to measure for longer.
Expert Q&As. Send your questions ahead of interviews like this one.
Your pod. Each month, an optional small group of carriers with similar monthly goals, helping each other stay on track.
89% of members see improvement in key APOE4 biomarkers within 3 months.
As a carrier myself, I was sick (pun intended) of not being able to trust recommendations when someone was paid to promote them (hello AG1). So here is how I keep Phoenix 100% independent: Phoenix earns revenue only from your membership, never from anything we recommend. Any commission we could take goes to you as a bigger discount. If we recommend something, it's because we believe it can help you. You buying it never earns Phoenix a cent.
For most members, the savings on bloodwork and supplements alone pay for Phoenix membership several times over.
Phoenix works beside your doctor, not instead of them.
Cheers,
Kevin
P.S. I carry two copies of APOE4. I built Phoenix because I wanted to give myself the best chance of beating the odds. Now I'm building it for you too. Give it sixty days. If you don't feel Phoenix was worth it, tell me and I'll refund you myself. Apply to join Phoenix
Educational, not medical advice. Every trial is different: ask the study team. APOE4 is a risk factor, not a diagnosis.
Frequently asked questions
Should APOE4 carriers join Alzheimer's prevention trials?
Jessica Langbaum calls it a personal decision. Weigh the time commitment, whether you want to learn results such as your amyloid PET or p-tau217 status, and whether the risk of an experimental drug is acceptable to you. Research can't advance without volunteers.
Will I have to stop my supplements to join a trial?
Only if the trial protocol lists them as excluded, and only for the period it sets (sometimes about 30 days). The reason is safety: the interaction with the drug being tested isn't known.
Is it ethical to take people off their treatment for a placebo?
In heart disease and cancer, people keep their standard treatment. There is no approved treatment for Alzheimer's prevention yet, which is why a washout is considered ethical in prevention trials.
What do I get if I'm on placebo?
More medical attention, scans and blood tests than usual, and in many trials the option to move onto the active drug after the blinded period. Ask about it before you join.
Do trials pay for travel?
Many cover transport, parking, a car service or a hotel stay. It varies by study and site, so ask.
Will a trial redo tests I already have?
Often, yes: the study needs the raw data, collected its way, with a chain of custody. Your existing results still make it less likely you'll fail screening.
Trials mentioned: PrevenTRON (Roche, trontinemab), announced at AAIC 2026, London, July (Roche). SPINOZA (NewAmsterdam, obicetrapib), NCT07794670.
Dr. Kevin Tran
Doctor of PharmacyDr. Kevin Tran is a Doctor of Pharmacy and APOE4/4 carrier dedicated to helping others with the APOE4 gene variant take proactive steps for their health. He founded The Phoenix Community to provide evidence-based resources and support for APOE4 carriers.
View all articles→
